Podcast
Questions and Answers
Which antibody has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL)?
Which antibody has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL)?
- Obinutuzumab
- Chlorambucil
- Rituximab (correct)
- GA101
What is the primary end point of the study?
What is the primary end point of the study?
- Response rate
- Overall survival
- Adverse events
- Investigator-assessed progression-free survival (correct)
What is the range of the Cumulative Illness Rating Scale (CIRS)?
What is the range of the Cumulative Illness Rating Scale (CIRS)?
- 0 to 10
- 0 to 56 (correct)
- 0 to 20
- 0 to 40
What is the median age of the patients in the study?
What is the median age of the patients in the study?
What is the estimated creatinine clearance of the patients in the study?
What is the estimated creatinine clearance of the patients in the study?
Which antibody was investigated in this study as compared to rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions?
Which antibody was investigated in this study as compared to rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions?
What was the primary end point of the study?
What was the primary end point of the study?
What was the median age of the patients in the study?
What was the median age of the patients in the study?
What was the range of the Cumulative Illness Rating Scale (CIRS)?
What was the range of the Cumulative Illness Rating Scale (CIRS)?
What was the estimated creatinine clearance of the patients in the study?
What was the estimated creatinine clearance of the patients in the study?
Flashcards are hidden until you start studying
